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Before the sorafenib era, advanced but liver-confined hepatocellular carcinoma (HCC) was treated by liver-
directed therapy. Hepatic arterial concurrent chemoradiotherapy (CCRT) has been performed in our group,
giving substantial local control but frequent failure. The aim of this study was to analyze patterns of failure
and find out predictive clinical factors in HCC treated with a liver-directed therapy, CCRT. A retrospective
analysis was done for 138 HCC patients treated with CCRT between May 2001 and November 2009.
Protocol-based CCRT was performed with local radiotherapy (RT) and concurrent 5-fluorouracil (5-FU)
hepatic arterial infusion chemotherapy (HAIC), followed by monthly HAIC (5-FU and cisplatin). Patterns
of failure were categorized into three groups: infield, intrahepatic-outfield and extrahepatic failure. Treatment
failure occurred in 34.0% of patients at 3 months after RT. Infield, intrahepatic-outfield and extrahepatic
failure were observed in 12 (8.6%), 26 (18.7%) and 27 (19.6%) patients, respectively. Median progression-
free survival for infield, outfield and extrahepatic failure was 22.4, 18 and 21.5 months, respectively. For
infield failure, a history of pre-CCRT treatment was a significant factor (P = 0.020). Pre-CCRT levels of
alpha-fetoprotein and prothrombin induced by vitamin K absence or antagonist-II were significant factors for
extrahepatic failure (P = 0.029). Treatment failures after CCRT were frequent in HCC patients, and were more
commonly intrahepatic-outfield and extrahepatic failures than infield failure. A history of pre-CCRT treatment
and levels of pre-CCRT tumor markers were identified as risk factors that could predict treatment failure.
More intensified treatment is required for patients presenting risk factors.
Keywords: hepatocellular carcinoma; hepatic arterial concurrent chemoradiotherapy (CCRT); patterns of
failure; risk factors
INTRODUCTION
The Barcelona Clinic Liver Cancer (BCLC) treatment guide-
lines divide patients diagnosed with hepatocellular carcin-
oma (HCC) into very early, early, intermediate, advanced
and terminal stages [1]. While very early and early-stage
patients would be candidates for curative therapy, those with
intermediate or advanced stage are not. Unfortunately, more
than 80% of HCC patients are diagnosed at an advanced
stage, with poor prognosis and a lack of effective therapies.
Recently, a multicenter, randomized, double-blind, placebo-
controlled, phase 3 trial in western countries [2] has shown
that the median overall survival and time to progression of
patients treated with sorafenib were nearly 3 months longer
than for placebo treatment. The positive sorafenib finding has
also been observed in the Asian-Pacific population [3]. Thus,
the BCLC staging classification and treatment strategy recom-
mends sorafenib as a standard treatment of advanced HCC.
The BCLC advanced stage involves a wide spectrum of
diseases: vascular invasion (portal vein thrombosis), lymph
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node metastasis, distant metastasis, and mildly symptomatic
performance status (Eastern Cooperative Oncology Group
Grade 1/2). Although sorafenib is a standard of care, its
limited benefit urges further investigation of new approaches.
Particularly in liver-confined disease, a liver-directed therapy
is worth serious consideration.
Before the introduction of sorafenib, our group developed
a protocol-based hepatic arterial concurrent chemoradiother-
apy (CCRT) consisted of local radiotherapy (RT) and con-
current 5-fluorouracil (5-FU) hepatic arterial infusion
chemotherapy (HAIC), followed by monthly HAIC (5-FU
and cisplatin) for 6 months. Even though sorafenib was intro-
duced to medical practice in 2009, its high cost has been a
major barrier to routine clinical use in Korea. Therefore
CCRT has continued to be used in our clinic.
A pilot trial reported in 2008 showed a response rate of
45%, a 3-year overall survival rate of 24.1%, and a median
survival time of 13.1 months, which exceeds the previously
reported 6 months more than 2-fold [4]. This encouraged us
to continue this protocol-based CCRT. However, the results
are still unsatisfactory due to frequent failure. Intrahepatic-
outfield and extrahepatic metastases were frequently seen
after CCRT. To improve the therapeutic outcome of HCC
patients treated with CCRT, better understanding of patterns
of treatment failure is prerequisite. In this study, we aimed to
analyze patterns of failure and to find out predictive clinical
factors in HCC treated with a liver-directed therapy of
CCRT.
MATERIALS ANDMETHODS
Medical records of 138 HCC patients treated with CCRT in
Severance hospital between May 2001 and November 2009
were reviewed retrospectively. As yet, sorafenib has not been
introduced to routine medical practice in Korea.
The patient, tumor and treatment characteristics of the
study group are shown in Table 1. The median patient age
was 55 years (range, 33–79 years), and the ratio of males to
females was 7:1. The median follow-up period was 36
months for all patients. The number of patients with modi-
fied International Union Against Cancer (UICC) Stage
T3N0M0 and T4N0M0 was 24 (17.4%) and 86 (62.3%), re-
spectively. While CCRT was applied to locally advanced
HCC with T3 and T4 stage, 20 patients (14.5%) with T2
stage were also included due to large tumors of ~ 10 cm.
Portal vein thrombosis was observed in 77 patients (55.8%).
A total of 104 patients (75.4%) were newly diagnosed as
HCC (primary treatment group), and 34 patients (24.6%)
had been treated with another treatment modality before
CCRT (recurrence treatment group). Transarterial chemoem-
bolization (TACE) was the most common treatment before
CCRT.
The CCRT protocol in our institution consists of CCRT fol-
lowed by hepatic arterial chemotherapy, as described in our
previous study [4]. Before CCRT was started, a percutaneous
hepatic arterial catheter (chemoport) was inserted, then drug
distribution was simulated by hepatic angiography through the
chemoport. Concurrent continuous-infusion hepatic arterial
5-FU (at a dose of 500 mg/day) was delivered during the first
and last weeks of RT through the chemoport. One month after
CCRT, HAIC with 5-FU (at a dose of 500 mg/m2 for 5 h on
Days 1–3) and cisplatin (at a dose of 60 mg/m2 for 2 h on Day
2) were administered every 4 weeks for 3–12 cycles, according
to tumor response; these courses are termed ‘repeated HAIC’.
Repeated HAIC was stopped if disease progression was shown.
Three-dimensional conformal radiotherapy (3D-CRT) was
performed on 81.9% of patients, and intensity-modulated
radiotherapy was applied in the remaining 18.1%. The median
radiation dose was 45 Gy (range, 45–64.8 Gy), and the
median dose per fraction was 1.8 Gy (range, 1.8–2.95 Gy).
The median pre-CCRT serum level of the liver tumor
marker alpha-fetoprotein (AFP) was 570.4 IU/ml (range,
1.0–88 336.5), and 78 patients had levels > 200 IU/ml. The
median pre-CCRT level of the second marker, prothrombin
induced by vitamin K absence (PIVKA-II), was 1641 mAU/
ml (range, 10.0–2000.0), and 118 patients had serum levels
> 60 mAU/ml.
Tumor responses were evaluated using modified
Response Evaluation Criteria in Solid Tumors [5], defining
the viable tumor by its uptake of contrast agent in the arterial
phase of dynamic computed tomography or magnetic reson-
ance imaging. The tumor response was categorized as com-
plete response (CR), i.e. the disappearance of any
intratumoral arterial enhancement in all targets; partial re-
sponse (PR), at least a 30% decrease in the sum of diameters
of viable target lesions; progressive disease (PD), an in-
crease of at least 20% in the sum of the diameters of viable
target lesions; or as stable disease (SD), any cases that do
not qualify for either PR or PD.
Patterns of failure were categorized into three groups: infield
failure, intrahepatic-outfield failure, and extrahepatic failure.
Infield failure was defined as progression of the tumor within
the radiation field that covered the planning target volume.
Intrahepatic failure was defined as progression of the tumor
within the liver but outside of the radiation field. Extrahepatic
failure refers to distant metastasis in lung, bone, etc.
Overall survival, progression-free survival (PFS), and clin-
ical factors influencing each failure were analyzed using the
Kaplan-Meyer method. Multivariate analysis was performed
using the Cox-proportional hazard model, and P values were
calculated from the log-rank test.
RESULTS
Median follow-up time was 10.4 months (range, 0.4–92.4) in
all patients and 35.2 months (range, 13.9–92.4) in surviving
patients. The median overall survival time from the end of
RT was 11.1 months, and the survival rates at 1 and 2 years
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were 46.1% and 27.9%, respectively (Fig. 1). At the last
follow-up, 115 patients (83.3%) had died, the status of 2
(1.4%) was unknown, and 21 (15.2%) were still alive. Of the
patients who were alive, 16 patients had no evidence of
disease, and five were living with disease. The median PFS
for infield, intrahepatic-outfield and extrahepatic failures
were 22.4, 18 and 21.5 months, respectively. The 1-year PFS
rates for the same failure groups were 72.2, 62.1 and 56.6%,
respectively.
The treatment response was evaluated at 3 months after
finishing RT in the CCRT protocol (Table 2). Treatment
failure occurred in 34.0% of the patients within 3 months
after RT. Details of treatment failure are shown in Fig. 2.
During the whole period of follow-up, treatment failure oc-
curred in 106 patients (76.8%) and 46 patients (33.3%) had
infield failure. Intrahepatic-outfield and extrahepatic failures
were more common than infield failure. The sites of extrahe-
patic failure, in order of frequency, were lung, distant lymph
Table 1. Patient characteristics
Characteristics No. of Patients (%)
Age (median year) 55 (range, 33–79)
< 50 37 (26.8)
≥ 50 101 (73.2)
Gender
Male 120 (87.0)
Female 18 (13.0)
Viral type
B 116 (84.1)
C 9 (6.5)
non-B, non-C 13 (9.4)
Child-Pugh class
A 125 (90.6)
B 13 (9.4)
ICG R15 (median %) 10.8 (range, 1.4–70.9)
Modified UICC stage
II
T2N0M0 20 (14.5)
III
T3N0M0 65 (47.1)
IVA
T4N0M0 41 (29.7)
T2N1M0 1 (0.7)
T3N1M0 10 (7.2)
T4N1M0 1 (0.7)
Portal vein thrombosis
No 61 (44.2)
Yes 77 (55.8)
Lymph node metastasis
No 126 (91.3)
Yes 12 (8.7)
Pre-CCRTAFP (median IU/ml) 570.4 (range, 1.0–88 336.5)
< 200 60 (43.5)
≥ 200 78 (56.5)
Pre-CCRT PIKVA-II (median
mAU/ml)
1641 (range, 10.0–2 000.0)
< 60 17 (12.6)
≥ 60 118 (87.4)
Pre-CCRT treatment history
No (primary treatment group) 104 (75.4)
Continued
Table 1. Continued
Characteristics No. of Patients (%)
Yes (recurrence treatment group) 34 (24.6)
Contents of pre-CCRT treatment
TACE 19 (55.9)
TACE, internal RT
(Holmium-166)
4 (11.8)
TACE, RFA 3 (8.8)
TACE, surgery 1 (2.9)
TACE, systemic chemotherapya 1 (2.9)
TACE, internal RT
(Holmium-166), Sorafenib
1 (2.9)
RFA 1 (2.9)
Intra-arterial chemotherapyb 2 (5.9)
Internal RT (Holmium-166) 1 (2.9)
Radiotherapy technique
3D CRT 113 (81.9)
IMRT 25 (18.1)
Total dose (median Gy) 45.0 (range, 45.0–64.8)
Dose/fraction (median Gy) 1.8 (range, 1.8–3.0)
ICG = indocyanine green, UICC = International Union
Against Cancer, CCRT = concurrent chemoradiotherapy,
TACE= transarterial chemoembolization, RT = radiation therapy,
RFA = radiofrequency ablation, AFP = alpha-feto-protein,
PIVKA-II = protein induced by vitamin K absence, 3D
CRT = three-dimensional conformal radiation therapy,
IMRT = intensity-modulated radiation therapy.
aSystemic adriamycin/cisplatin.
bCisplatin 1, fluorouracil/cisplatin 1.
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node, bone, peritoneal seeding, adrenal gland, pleura and
brain.
About half of treatment failure was combined with other
categories of failure such as infield with intrahepatic-outfield
failure, or infield with extrahepatic failure; 7 of 12 infield
failures, 13 of 26 intrahepatic-outfield failures, and 14 of 27
extrahepatic failures.
The association of clinical factors involving age, sex,
stage, portal vein thrombosis, treatment history and
pre-CCRT tumor marker level were analyzed by univariate
and multivariate analysis for prognostic significance for PFS
(Table 3 and Fig. 3). The PFS for infield failure was
improved in patients in the primary treatment group com-
pared with patients in the recurrence treatment group (at 2
years after RT, PFS of 53.5% vs 29.6%, P = 0.035). Other
clinical factors including T stage, tumor size and RT dose
were not associated with local control. Both the elevation of
pre-CCRT AFP levels (≥200 IU/ml) and PIVKA-II (≥60
mAU/ml) were significant factors for intrahepatic-outfield
failure (at 2 years after RT, PFS 43.5% vs 38.7%, P = 0.005).
For extrahepatic failure, an age of <50 years was a significant
factor (P = 0.007), as were biomarker levels of AFP ≥200 IU/
ml and PIVKA-II ≥60 mAU/ml (P = 0.003). In multivariate
analysis, the levels of the two biomarkers were not associated
with intrahepatic-outfield failure, but they were the only sig-
nificant factors identified as associated with extrahepatic
failure.
Although data was not shown, we also analyzed the clinic-
al factors related to overall survival. T3/4 stage, Child-Pugh
class B, infield failure at 3 months after finishing RT and
both the elevation of pre-CCRT AFP levels (≥200 IU/ml)
and PIVKA-II (≥60 mAU/ml) were significant factors in
multivariate analysis.
Toxicity during CCRT and the following 3 months has
been summarized in Table 4. Neutropenia ≥Grade 3 and
thrombocytopenia ≥Grade 3 were observed in 17 and 23
patients, respectively. Five patients had severe gastroduode-
nal toxicities such as gastritis, duodenitis or an ulcer. Of the
138 patients, 20 had died 3 months after CCRT, and hepatic
failure was the cause of death in 13 patients. Hepatic failure
seemed to have resulted from complex factors involving
treatment and disease progression.
DISCUSSION
Liver-directed therapy, consisting of local radiotherapy and
concurrent HAIC, has been demonstrated as prolonging sur-
vival in patients with liver-confined HCC [4, 6–9]. Ben-Josef
et al. performed high-dose 3D-CRT (median 60.75 Gy in
1.5 Gy per fraction, twice daily, range 40–90 Gy) with con-
current HAIC with floxuridine (0.2 mg/kg/day) [9]. Out of
128 patients in their study, 35 had HCC and showed amedian
overall survival of 15.2 months. Han and Seong et al. [4]
used concurrent 5-FU HAIC (500 mg/day) and 3D-CRT (45
Fig. 1. Overall survival and progression-free survival curves. The
1-year survival rate was 46.1% and median overall survival (OS)
was 11.1 months. Progression-free survival rates at 1 year after RT
were 72.2%, 62.1%, and 56.6% for infield, intrahepatic-outfield,
and extrahepatic failures, respectively. The median PFS for the
same failure groups were 22.4, 18, and 21.5 months, respectively.
Fig. 2. Patterns of failure. Patterns of failure were categorized into
three groups; infield, intrahepatic-outfield, and extrahepatic failures.
At 3 months after concluding RT in the CCRT protocol, treatment
failures occurred in 47 patients (34.0%).
Table 2. Treatment response at 3 months after radiotherapy
Response No. (%)
Complete response 4 (2.9)
Partial response 77 (55.8)
Stable disease 45 (32.6)
Progressive disease 12 (8.7)
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Table 3. Risk factors of progression-free survival (PFS)
a) Univariate analysis
Local failure Distant failure
Infield failure Intrahepatic-outfield failure Extrahepatic failure
No. 2-year PFS (%) P-value No. 2-year PFS (%) P-value No. 2-year PFS (%) P-value
Age (y)
< 50 37 54.8 0.907 37 26.6 0.309 37 26.2 0.007
≥ 50 101 44.5 101 43.5 101 48.9
Stage
II 20 59.8 0.474 20 40.7 0.610 20 60.8 0.116
III-IV 118 46.3 118 40.5 118 40.2
Portal vein thrombosis
No 61 55.2 0.233 61 40.6 0.275 61 36.6 0.443
Yes 77 38.5 77 39.3 77 52.3
Pre-CCRT Treatment history
Primary treatment group 104 53.5 0.035 104 38.5 0.892 104 41.8 0.314
Recurrence treatment group 34 29.6 34 41.6 34 48.3
Pre-CCRTAFP (IU/ml)
< 200 60 43.5 0.916 60 42.7 0.062 60 44.8 0.087
≥ 200 78 53.8 78 38.8 78 43.7
Pre-CCRT PIVKA-II (mAU/ml)
< 60 17 51.4 0.962 17 53.2 0.160 17 60.5 0.177
≥ 60 118 44.9 118 36.2 118 40.2
Pre-CCRTAFP & PIVKA-II
≥ 200 & ≥60 67 50.3 0.465 67 38.7 0.005 67 42.4 0.003
< 200 &/or <60 68 46.2 68 43.5 68 48.4
Continued
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Table 3. Continued
b) Multivariate analysis
Local failure Distant failure
Infield failure Intrahepatic-outfield failure Extrahepatic failure
HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value
Age 0.742 0.360–1.531 0.420 0.853 0.480–1.518 0.589 0.680 0.382–1.209 0.189
≥ 50
Stage 1.036 0.431–2.493 0.937 0.878 0.426–1.810 0.724 1.869 0.845–4.134 0.122
III–IV
Portal vein thrombosis 1.386 0.725–2.651 0.324 1.267 0.729–2.203 0.401 0.669 0.398–1.126 0.131
Yes
Pre-CCRT treatment history 2.190 1.132–4.235 0.020 1.198 0.677–2.120 0.536 0.858 0.458–1.606 0.631
Recurrence treatment group
Pre-CCRTAFP (IU/ml) 0.444 0.096–2.048 0.298 1.045 0.231–4.726 0.954 0.242 0.046–1.276 0.094
≥ 200
Pre-CCRT PIVKA-II (mAU/ml) 0.742 0.250–2.207 0.592 1.422 0.423–4.784 0.569 0.602 0.223–1.622 0.315
≥ 60
Pre-CCRTAFP & PIVKA-II
≥ 200 and ≥60 2.511 0.485–12.997 0.272 1.740 0.353–8.587 0.496 6.949 1.219–39.614 0.029
PFS = progression-free survival, CCRT = concurrent chemoradiotherapy, AFP = alpha-feto-protein, PIVKA-II = protein induced by vitamin K absence; HR, hazard ratio;
CI, confidence interval.
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Gy in 25 fractions), followed by monthly HAIC. The median
survival time of 40 patients with advanced but liver-confined
HCC was 13.1 months and the median for PFS was 6
months. Although lack of a phase III randomized study
excludes this approach as a standard of care for advanced
HCC, the therapeutic outcome seems promising with a
longer survival time compared with that for sorafenib treat-
ment, suggesting that this would be worthy of active investi-
gation for a subgroup of advanced HCC patients.
In our study, the median PFS was 22.4, 18 and 21.5
months for infield, intrahepatic-outfield and extrahepatic fail-
ures, respectively. Intrahepatic-outfield and extrahepatic fail-
ures were more common than infield failure. Treatment
failure still remains to be overcome, particularly
intrahepatic-outfield and extrahepatic failures. We identified
several factors influencing each of the three types of treat-
ment failure. A history of pre-CCRT treatment was signifi-
cantly associated with infield failure. Patients with
sufficiently high pre-CCRT serum levels of the two biomar-
kers AFP and PIVKA-II showed significantly longer PFS.
Patients treated with other modalities before CCRT, most
frequently TACE (85.2%), had worse infield PFS. The
BCLC guidelines recommend TACE for patients in
Fig. 3. Progression-free survival (PFS) of treatment failure by risk factor. (a) PFS of infield failure was improved in patients treated with
CCRT as the initial treatment (primary treatment group). A history before pre-CCRT treatment was also identified as a significant factor in
multivariate analysis (P = 0.020). (b) Both the elevation in the pre-CCRT levels of AFP (≥200 IU/ml) and PIVKA-II (≥60 mAU/ml) were
significant factors for intrahepatic-outfield failure. However, changes in the levels of these tumor markers were not significant in multivariate
analysis (P = 0.496). (c, d) Patients <50 years of age and with incremental changes in the levels of pre-CCRT AFP (≥200 IU/ml) and
PIVKA-II (≥60 mAU/ml) showed poorer PFS for extrahepatic failure. Incremental changes in the levels of the pre-CCRT tumor marker were
the only significant factor identified in multivariate analysis (P = 0.029).
Table 4. Toxicity during CCRT and the following 3 months
Toxicity Grade 3 No. (%) Grade 4 No. (%)
Neutropenia 14 (10.1%) 3 (2.2%)
Anemia 2 (1.4%) 3 (2.2%)
Thrombocytopenia 21 (15.2%) 2 (1.4%)
AST elevation 19 (13.8%) 8 (5.8%)
ALT elevation 11 (8.0%) 2 (1.4%)
Bilirubin elevation 5 (3.6%) 11 (8.0%)
GI – mucositis, ulcer 5 (3.6%) 0
AST = aspartate transaminase, ALT = alanine
aminotransferase, GI = gastrointestinal.
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intermediate-stage HCC [1]. Currently, TACE is the most
popular nonsurgical treatment for HCC in Asia. However,
TACE frequently fails to induce complete necrosis, and this
may result in residual viable tumor [10, 11]. The mechanism
of TACE is extensive ischemic necrosis by hepatic artery ob-
struction with embolic material. In this process, tissue
hypoxia can be induced, which increases expression of
angiogenic factor. The latter stimulates the proliferative ac-
tivity of intratumoral endothelial and tumor cells in the re-
sidual HCC after TACE [11, 12], which can further induce
resistance to either chemotherapy or radiotherapy. These
effects may also facilitate intra- or extrahepatic metastasis.
The lung is the most common site of extrahepatic metastasis,
and an increased risk of lung metastasis after TACE has been
reported. Since vascular endothelial growth factor (VEGF) is
a key factor in angiogenesis, an increase in VEGF levels
after TACE may induce development of collateral blood
vessels, nourishing the surviving residual tumor tissue [10,
13, 14]. A possible relationship between VEGF levels and
treatment failure has been investigated in patients treated by
TACE [10, 13]. This relationship between VEGF levels and
treatment failure might also be relevant in patients treated
with CCRT.
In our previous reports, addition of RT improved tumor re-
sponse and survival both for patients with TACE failure and
for patients with incomplete TACE [15–17]. Dose escalation
has been considered to increase local control rates [18]. In
our study, a history of pre-CCRT treatment was identified as
a risk factor for infield failure, suggesting a need for more in-
tensified local treatment for this recurrence treatment group.
In this regard, the dose of 45 Gy in our CCRT protocol
needs to be escalated according to the patients’ subgroup.
Subgroup analysis was done for patients with or without a
history of pre-CCRT treatment. Median pre-CCRT AFP
levels were 664.5 IU/ml in the primary treatment group and
527.6 IU/ml in the recurrence treatment group, and the
median pre-CCRT PIVKA-II levels were 2000.0 mAU/ml
and 610.0 mAU/ml, respectively. In the primary treatment
group, elevation of AFP and PIVKA-II was a significant
factor in outfield and extrahepatic PFS (P = 0.002 and 0.003,
respectively). However, the factor was not significant in the re-
currence treatment group (P = 0.171 and 0.07, respectively).
Levels of both AFP and PIVKA-II before CCRT were
associated with extrahepatic failure. The serum indicators
AFP and PIVKA-II are the most commonly used tumor
markers in HCC, and it is well known that an HCC with high
levels of AFP and PIVKA-II is associated with more aggres-
sive tumor behavior, e.g. large numbers of tumors, frequent
vascular invasion, early intrahepatic and distant metastasis,
and poor prognosis [19–21]. In our study, elevation of only
one of the biomarkers was not significant for treatment
failure, but elevation of pre-CCRT levels of both was signifi-
cant. As shown in Fig. 3d, differences in the survival curves
according to the pre-CCRT tumor markers were marked in
early period of follow-up. Ultimately, difference in PFS
seemed to be minimal with longer follow-up. Therefore,
pre-CCRT levels of tumor markers could be helpful for pre-
dicting early failure.
Since our protocol-based CCRT consisted of local RT and
regional chemotherapy through HAIC, a component of sys-
temic treatment was omitted. Our results suggest that system-
ic treatment is necessary for a subgroup of patients.
In this study, we have identified risk factors for treatment
failure: history of pre-CCRT treatment, as a factor associated
with infield failure; and elevation of both AFP and
PIVKA-II levels before CCRT, as a risk factor for extrahepa-
tic failure. This suggests that more intensified treatment is
required for the patients presenting risk factors; intensifica-
tion of local treatment for those with a past treatment history,
and more effective systemic treatment for those with elevated
serum tumor markers. Since sorafenib is the only recom-
mended systemic agent at present, a novel approach combin-
ing sorafenib and CCRT needs further investigation.
CONCLUSION
Treatment failure was frequent in HCC patients treated with a
liver-directed therapy of CCRT, more commonly intrahepatic-
outfield and extrahepatic failures than infield failure at 3
months after RT. A history of pre-CCRT treatment, as well as
levels of pre-CCRT tumor markers, were identified as risk
factors that can predict treatment failure. More intensified
treatment is required for the patients presenting risk factors.
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